logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics halted with capital raising announcement pending

The halt will remain in place until the start of ASX trading on Wednesday, February 5 or when an announcement is released.

Zelira Therapeutics Ltd. - Zelira Therapeutics halted with capital raising announcement pending
Zelira has announced a collaboration agreement with the Parkinson’s Foundation in the US

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is in a trading halt pending the release of a capital raising announcement.

The halt will remain in place until the start of regular ASX trading on Wednesday, February 5, 2020, or when an announcement is released to the market, whichever occurs first.

Zelira, which had a market cap of approximately $48 million, last traded at 6.5 cents, up from 5.2 cents on December 11.

Parkinson's Foundation collaboration

The company recently announced that it would collaborate with the Parkinson’s Foundation in the US to gather insights from people living with Parkinson’s Disease about their understanding of and use of medical cannabis and hemp-derived therapies.

Zelira and the Parkinson’s Foundation will consult on the development of a survey tool to be sent to people with the diseases to understand why and how they are using medical cannabis and hemp-derived CBD products.

They will review the results as they relate to a possible future clinical trial on the safety and efficacy of medical cannabis use by people with Parkinson’s Disease.

Zelira will also incorporate survey insights to inform future development of clinically validated medical cannabis and hemp-derived CBD medicines for people with the disease, and provide guidance to sufferers regarding various cannabinoid-based and hemp-derived CBD treatment alternatives.

Quick facts: Zelira Therapeutics Ltd

Price: 0.035 AUD

ASX:ZLD
Market: ASX
Market Cap: $33.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read